



General Assembly

**Raised Bill No. 129**

February Session, 2016

LCO No. 1239



Referred to Committee on PUBLIC HEALTH

Introduced by:  
(PH)

**AN ACT CONCERNING INSURANCE COVERAGE FOR ABUSE-  
DETERRENT OPIOID ANALGESICS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2017*) (a) As used in this  
2 section, (1) "opioid analgesic" means a drug product that contains an  
3 opioid agonist and is approved by the federal Food and Drug  
4 Administration for the treatment of pain, whether in immediate release  
5 or extended release form, and whether or not combined with other  
6 drug substances to form a single drug product or dosage, and (2)  
7 "abuse-deterrent opioid analgesic" means an opioid analgesic with  
8 labeling that indicates the drug's abuse-deterrent properties are  
9 expected to deter or reduce the abuse of such drug.

10 (b) Each insurance company, health care center, hospital service  
11 corporation, medical service corporation, fraternal benefit society or  
12 other entity that delivers, issues for delivery, renews, amends or  
13 continues any individual health insurance policy providing coverage  
14 of the type specified in subdivisions (1), (2), (4), (11), (12) and (16) of  
15 section 38a-469 of the general statutes and that provides coverage for  
16 prescription drugs shall provide coverage for at least one abuse-

17 deterrent opioid analgesic per opioid analgesic active ingredient.

18 (c) Notwithstanding subdivision (2) of subsection (a) and  
19 subdivision (1) of subsection (b) of section 38a-510 of the general  
20 statutes, no such company, center, corporation, society or other entity  
21 shall require an insured to use a non-abuse-deterrent opioid analgesic  
22 prior to using an abuse-deterrent opioid analgesic.

23 Sec. 2. (NEW) (*Effective January 1, 2017*) (a) As used in this section,  
24 (1) "opioid analgesic" means a drug product that contains an opioid  
25 agonist and is approved by the federal Food and Drug Administration  
26 for the treatment of pain, whether in immediate release or extended  
27 release form, and whether or not combined with other drug substances  
28 to form a single drug product or dosage, and (2) "abuse-deterrent  
29 opioid analgesic" means an opioid analgesic with labeling that  
30 indicates the drug's abuse-deterrent properties are expected to deter or  
31 reduce the abuse of such drug.

32 (b) Each insurance company, health care center, hospital service  
33 corporation, medical service corporation, fraternal benefit society or  
34 other entity that delivers, issues for delivery, renews, amends or  
35 continues any group health insurance policy providing coverage of the  
36 type specified in subdivisions (1), (2), (4), (11), (12) and (16) of section  
37 38a-469 of the general statutes and that provides coverage for  
38 prescription drugs shall provide coverage for at least one abuse-  
39 deterrent opioid analgesic per opioid analgesic active ingredient.

40 (c) Notwithstanding subdivision (2) of subsection (a) and  
41 subdivision (1) of subsection (b) of section 38a-544 of the general  
42 statutes, no such company, center, corporation, society or other entity  
43 shall require an insured to use a non-abuse-deterrent opioid analgesic  
44 prior to using an abuse-deterrent opioid analgesic.

This act shall take effect as follows and shall amend the following sections:		
Section 1	January 1, 2017	New section

Sec. 2	<i>January 1, 2017</i>	New section
--------	------------------------	-------------

***PH***

*Joint Favorable C/R*

INS